Gilead Sciences
-
Vanderbilt researchers take leadership role in COVID-19 vaccine development
Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes. Read MoreDec. 18, 2020
-
COVID treatment studied by VUMC gains FDA approval
Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19. Read MoreOct. 26, 2020
-
New study supports remdesivir as COVID-19 treatment
This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus. Read MoreJul. 9, 2020